Journal
ACS NANO
Volume 14, Issue 4, Pages 5075-5089Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.0c01676
Keywords
nanoparticles; drug delivery; membrane-core nanostructure; immunogenic cell death; combination therapy
Categories
Funding
- NIH [CA198999]
- Talents Cultivation Program of Jilin University
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China [81774240, 81403272]
- China Scholarship Council [201808310047]
- Chenguang Program from Shanghai Education Development Foundation [15CG48]
- Chenguang Program from Shanghai Municipal Education Commission [15CG48]
- Shanghai Rising-Star Program [17QA1403900]
- Training Plan of Outstanding Young Medical Talents from Shanghai Municipal Health Bureau [2017YQ021]
- Talent Youth Supporting Project from Chinese Medicine Association [QNRC2-C14]
Ask authors/readers for more resources
FOLFOX, the combinational strategy of folinic acid (FnA), 5-fluorouracil (5-Fu), and oxaliplatin (OxP), has been used as standard treatment of colorectal cancer (CRC) for decades. Despite the improved survival, patients still suffer from drawbacks such as low efficacy, high toxicity, and long course of treatment. New strategies to address these issues are needed to further clinical benefits. In this study, a nanoprecipitate (C26H35N9O7Pt) was formed by the active form of OxP ([Pt(DACH)(H2O)(2)](2+) and FnA, which was formulated into an aminoethyl anisamide targeted PEGylated lipid nanoparticle within microemulsions using nanoprecipitation technique. The resultant formulation (namely Nano-Folox) significantly promoted the blood circulation and tumor accumulation of platinum drug and FnA in an orthotopic CRC mouse model. Emerging evidence indicates that OxP can not only provide anticancer cytotoxic effects but also induce immunogenic cell death (a type of apoptosis that primes anticancer immune responses). Consequently, Nano-Folox demonstrated favorable chemo-immunotherapeutic activities in orthotopic CRC mice. In addition, when compared to FOLFOX the significantly stronger chemo-immunotherapeutic responses were achieved by the combination of Nano-Folox and 5-Fu without showing toxicity. Moreover, the anti-PD-L1 monoclonal antibody enhanced Nano-Folox/5-Fu for decreased liver metastases in mice. These results indicate the potential of Nano-Folox-based combination strategy for the treatment of CRC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available